BC Innovations | Sep 13, 2019
Distillery Therapeutics

Treating antibiotic-resistant Gram-negative infection with stapled antimicrobial peptides

DISEASE CATEGORY: Infectious disease INDICATION: Gram-negative bacterial infection; sepsis Stapled antimicrobial peptides could treat antibiotic-resistant Gram-negative infections, including Acinetobacter baumanii -induced sepsis. The compounds consisted of stapled peptides derived from the antimicrobial peptide (AMP) magainin...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
BC Week In Review | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

The partners established DepYmed Inc., a JV to develop Ohr's trodusquemine and related analogs for an undisclosed indication. The partners will initially have equal ownership of DepYmed. Cold Spring will conduct preclinical testing of the...
BC Week In Review | Apr 15, 2013
Clinical News

Magainin preclinical data

NIH researchers reported that MSI-1436 inhibits HIV replication in vitro by interfering with immune cell activation. The compound, isolated from the dogfish shark, blocks a cell surface ion exchange protein in infected cells but does...
BC Week In Review | Apr 15, 2013
Company News

SunPharm board of directors update

SunPharm Corp. (SUNP), Jacksonville, Fla.   Business: Autoimmune/Inflammation, Cancer, Infectious diseases   Appointed: Jay Moorin, president and CEO of Magainin Pharmaceuticals Inc. , as chairman  ...
BC Week In Review | Oct 31, 2011
Clinical News

MEDI-528: Development discontinued

AstraZeneca disclosed in its 3Q11 earnings that it discontinued development of MEDI-528 due to the product's "lack of efficacy" in a Phase IIb trial to treat uncontrolled, moderate to severe, persistent asthma. Ligand was eligible...
BC Extra | Oct 28, 2011
Clinical News

AstraZeneca discontinues MEDI-528

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it discontinued development of MEDI-528 due to the product's "lack of efficacy" in a Phase IIb trial to treat uncontrolled, moderate to severe, persistent asthma. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was...
BC Innovations | Oct 6, 2011
Targets & Mechanisms

Shark versus virus

Over the past 18 years, the aminosterol squalamine has changed corporate hands twice and been tried in indications ranging from cancer to age-related macular degeneration. Now, the academic who originally isolated the compound from dogfish...
BC Week In Review | Jul 25, 2011
Clinical News

Ohr preclinical data

In rabbits, a single drop of topical squalamine eye drops to the front of the eye entered the posterior sclera-choroid region behind the retina in concentrations known to block choroidal neovascularization. Additionally, the topical eye...
BC Week In Review | Mar 7, 2011
Clinical News

MEDI-528: Completed Phase IIb enrollment

Ligand disclosed in its 4Q10 earnings that AstraZeneca's MedImmune LLC unit completed enrollment of 320 patients in an open-label, placebo-controlled Phase IIb trial evaluating 30, 100 and 300 mg subcutaneous MEDI-528. Last May, Ligand acquired...
Items per page:
1 - 10 of 321
BC Innovations | Sep 13, 2019
Distillery Therapeutics

Treating antibiotic-resistant Gram-negative infection with stapled antimicrobial peptides

DISEASE CATEGORY: Infectious disease INDICATION: Gram-negative bacterial infection; sepsis Stapled antimicrobial peptides could treat antibiotic-resistant Gram-negative infections, including Acinetobacter baumanii -induced sepsis. The compounds consisted of stapled peptides derived from the antimicrobial peptide (AMP) magainin...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
BC Week In Review | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

The partners established DepYmed Inc., a JV to develop Ohr's trodusquemine and related analogs for an undisclosed indication. The partners will initially have equal ownership of DepYmed. Cold Spring will conduct preclinical testing of the...
BC Week In Review | Apr 15, 2013
Clinical News

Magainin preclinical data

NIH researchers reported that MSI-1436 inhibits HIV replication in vitro by interfering with immune cell activation. The compound, isolated from the dogfish shark, blocks a cell surface ion exchange protein in infected cells but does...
BC Week In Review | Apr 15, 2013
Company News

SunPharm board of directors update

SunPharm Corp. (SUNP), Jacksonville, Fla.   Business: Autoimmune/Inflammation, Cancer, Infectious diseases   Appointed: Jay Moorin, president and CEO of Magainin Pharmaceuticals Inc. , as chairman  ...
BC Week In Review | Oct 31, 2011
Clinical News

MEDI-528: Development discontinued

AstraZeneca disclosed in its 3Q11 earnings that it discontinued development of MEDI-528 due to the product's "lack of efficacy" in a Phase IIb trial to treat uncontrolled, moderate to severe, persistent asthma. Ligand was eligible...
BC Extra | Oct 28, 2011
Clinical News

AstraZeneca discontinues MEDI-528

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it discontinued development of MEDI-528 due to the product's "lack of efficacy" in a Phase IIb trial to treat uncontrolled, moderate to severe, persistent asthma. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was...
BC Innovations | Oct 6, 2011
Targets & Mechanisms

Shark versus virus

Over the past 18 years, the aminosterol squalamine has changed corporate hands twice and been tried in indications ranging from cancer to age-related macular degeneration. Now, the academic who originally isolated the compound from dogfish...
BC Week In Review | Jul 25, 2011
Clinical News

Ohr preclinical data

In rabbits, a single drop of topical squalamine eye drops to the front of the eye entered the posterior sclera-choroid region behind the retina in concentrations known to block choroidal neovascularization. Additionally, the topical eye...
BC Week In Review | Mar 7, 2011
Clinical News

MEDI-528: Completed Phase IIb enrollment

Ligand disclosed in its 4Q10 earnings that AstraZeneca's MedImmune LLC unit completed enrollment of 320 patients in an open-label, placebo-controlled Phase IIb trial evaluating 30, 100 and 300 mg subcutaneous MEDI-528. Last May, Ligand acquired...
Items per page:
1 - 10 of 321